IVD Distributors' Delegation Visits Weigao Shengji for Strategic Exchange and Product Showcase
WEGO
Medical Device and Pharmaceutical R&D Manufacturer
On May 26, 2026, distribution entrepreneurs from across China gathered in Weihai to visit WEGO Shengji for inspection and exchange activities, conducted field visits to the headquarters of Weigao Group, discussed development trends in the IVD industry, and explored new pathways for channel cooperation.
That afternoon, the entrepreneurs arrived at the headquarters of WEGO Group. Accompanied by senior executives including Huang Zuming, General Manager of WEGO Shengji Medical Industry Group; Xia Fuzhen, Chief Scientist; and Sun Qingdong, Deputy General Manager and General Manager of the Marketing Center, they toured the WEGO Group exhibition hall. Through product displays and case studies, the entrepreneurs gained a comprehensive understanding of WEGO Group’s development history, technological expertise, industrial layout, and innovative achievements. They closely experienced the company’s core strengths and profound heritage in the field of in vitro diagnostics (IVD), expressing high recognition of WEGO Shengji’s product advantages and industry influence.
Following the tour, the WEGO Group IVD Distributor Strategic Partnership Exchange Meeting was held as scheduled. Presided over by Sun Qingdong, the meeting centered on the theme “Integration, Innovation, Harmony, and Win-Win Cooperation,” with in-depth discussions focusing on industry trends, channel ecosystem, and collaboration planning.
At the meeting, Huang Zuming, General Manager of WEGO Shengji Medical Industry Group, delivered a welcome address, extending warm greetings to the attending distribution entrepreneurs. He expressed gratitude to partners from all sectors for their long-standing support and trust, articulated a vision for deepening channel cooperation to achieve mutual benefit and win-win outcomes, and looked forward to establishing long-term strategic partnerships through in-depth exchanges.
Song Haibo, Vice President of the China National Association of Health Industry and Enterprise Management and President of its Medical Laboratory Industry Branch, and Wang Hualiang, Chairman of the Association’s Committee on Laboratory Medicine and Dean of the Shanghai Institute of Laboratory Medicine, delivered opening remarks in succession. Grounding their perspectives in the overall development of the industry, they analyzed the new landscape, opportunities, and challenges currently facing the in vitro diagnostics (IVD) distribution channel. From a professional standpoint, they provided guidance for promoting high-quality industry development and optimizing the channel ecosystem, offering profound insights to the attending guests.
Subsequently, Liu Huiyong, Brand Strategy Director of WEGO Shengji, introduced the group’s overall profile and the strategic layout of its in vitro diagnostics (IVD) business. Peng Juan, Marketing Director and General Manager of the Overseas Business Division, then highlighted WEGO Shengji’s distinctive products, including innovative offerings such as Helicobacter pylori genotyping tests. These presentations sparked strong interest among the attending entrepreneurs, providing them with a clearer and more comprehensive understanding of the company’s industrial layout and product portfolio.
The interactive discussion session was marked by a vibrant atmosphere, with participating entrepreneurs engaging in lively exchanges on topics such as establishing a regular communication mechanism between WEGO Shengji and distribution enterprises. Attendees unanimously agreed that, in the face of normalized centralized procurement and the deepening of tiered diagnosis and treatment, distribution enterprises must accelerate their transformation from traditional logistics to comprehensive services, collaborating with upstream manufacturers to create integrated “diagnosis + service” solutions. Participants spoke freely, engaged in in-depth discussions, and actively offered suggestions and recommendations.
Finally,Vice President of the Medical Laboratory Industry Branch of the China National Health Industry Enterprise Management Association, General Manager of Medical Devices at Haiwang (Tianjin) Medical Technology Co., Ltd.Yin Liang concluded: “This visit to WEGO Shengji has not only deepened distributors’ understanding of upstream innovative technologies, but also laid a solid foundation for establishing a long-term and stable communication and cooperation platform in the future.” He expressed his expectation that both parties establish a regular communication mechanism and carry out cooperation in broader fields and at deeper levels.
The visit and exchange activity at WEGO Shengji effectively built a communication bridge between WEGO Shengji and distribution entrepreneurs, enhancing mutual trust, building consensus, and clarifying directions. In the future, all parties will uphold the philosophy of "integration and innovation, harmony and win-win cooperation," deepen resource integration and business synergy, and jointly explore new development spaces in the IVD industry.
Participants in this exchange event included:
Jin Hongsen, Co-founder of Wuhan Hanhai New Enzyme Biotechnology Co., Ltd., and Yao Gang, Manager of the Clinical Laboratory In Vitro Diagnostic Reagent Service Department in Shaanxi Province, both serve as Vice Presidents of the Medical Laboratory Industry Branch of the China National Health Industry Enterprise Management Association. Also attending the aforementioned event were Liu Zhengchun, President of the Shaanxi Medical Laboratory Products Association and General Manager of Chongqing Pharmaceutical Group Shaanxi Medical Technology Co., Ltd.; Wang Jingdong, General Manager of Tianjin Wanli Medical Technology Co., Ltd.; Chen Jibo, Director of the Office of the Professional Committee on Labelled Immunoassay of the Chinese Society for Analytical Testing; Zhou Yuan, Director of Sinopharm Holdings Guorun Medical Supply Chain Services (Shanxi) Co., Ltd.; Zhang Zhimin, General Manager of Hainan Ruida Kangyuan Investment Co., Ltd.; Qiu Youbin, Chairman of Huayue Health Industry Group; Yu Hongyue, General Manager of Heilongjiang Zhiding Jinhe Trading Co., Ltd.; Xu Zhen, General Manager of Yinchuan Shenli Science and Trade Co., Ltd.; Shu Xin, General Manager of Shandong Ruike Medical Technology Co., Ltd.; Guo Xing, Executive Director and General Manager of Shaanxi Huayuan Pharmaceutical Group Medical Device Co., Ltd.; Liu Dangwei, General Manager of Shaanxi Chuanding In Vitro Diagnostic Reagent Co., Ltd.; Wang Jifeng, General Manager of Jinan Donghe Shengtai Trading Co., Ltd.; Tang Fuxing, General Manager of Jinan Xinglin Supply Chain Management Co., Ltd.; Xie Chunming, General Manager of Chongqing Oumai Medical Equipment Co., Ltd.; Mao Tao, General Manager of Shanxi Guoxin Medical Investment Medical Device Co., Ltd.; Shi Lei, General Manager of Shanxi Beili Medical Technology Co., Ltd.; Wu Ganjun, Deputy General Manager of Kuoran Biomedical Technology (Shanghai) Co., Ltd.; Zhang Hongfang, General Manager of Xi'an Shenglang In Vitro Diagnostic Reagent Co., Ltd.; Zhou Hongjun, General Manager of Kunming Shijie Technology Development Co., Ltd.; Geng Hao, General Manager of Yunnan Houmai Huili Medical Device Co., Ltd.; Yang Fan, Vice President and Co-founder of Hangzhou Changji Medical Technology Co., Ltd.; Xiao Lu, General Manager of Jiangsu Huateng Medical Device Company; Ding Yanyan, General Manager of Liaoning Zhentong Supply Chain Co., Ltd.; Ji Zhe, General Manager of Shanxi Xinrun Technology Co., Ltd.; Jiang Ting, General Manager of Tianjin Impression Space Cultural Communication Co., Ltd.; Xu Zizhe, General Manager of Beijing Yiguangnian Biotechnology Co., Ltd.; Zhao Bing, Deputy Secretary-General of the Medical Laboratory Industry Branch of the China National Health Industry Enterprise Management Association and Executive Deputy General Manager of CACLP; and Fei Xiaozhou, Director of the Branch Office.
About WEGO Shengji
Weigao Shengji Medical is the core industrial group of Weigao Group in the field of in vitro diagnostics (IVD). Driven by the dual engines of “high-end intelligent manufacturing” and “innovative services,” it has built a full-chain solution spanning proprietary products, integrated services, and unattended smart laboratory ecosystems, committed to driving efficiency transformation and value reconstruction in the medical testing industry.
Leveraging WEGO’s deep, full-industry-chain expertise in the medical device sector, Shengji Group has achieved independent innovation and industrialization of key technologies in immunology, clinical chemistry, coagulation, microbiology, mass spectrometry, and laboratory consumables. It has pioneered a unique “Product + Service + Ecosystem” business model. By deploying a forward-looking “Comprehensive Smart Laboratory Ecosystem,” leading “6S Integrated Laboratory Services,” and “Regional Laboratory Informatics” solutions that set industry standards, Shengji Group systematically empowers hospitals at all levels and regional laboratory centers to achieve intelligent upgrades and lean operations, thereby leading the industry’s paradigm shift from equipment procurement to sustained value creation.
Upholding the mission of “Partnering with Healthcare Heroes to Pioneer a Healthy Future,” WEGO Shengji Medical is driving the development of new smart laboratory infrastructure through technological innovation and ecosystem synergy, committed to becoming a leading provider of valuable solutions in the field of in vitro diagnostics.
This article is a repost.If there is any infringement or restriction on reprinting, please contact us (or leave a message below the official account), and we will contact you and delete it as soon as possible.
Semen
Select
Recommend
Read
